Sichuan Biokin Pharmaceutical (SHA:688506) said the first patient was enrolled in its phase three trial for BL-B01D1, according to a Monday filing with the Shanghai bourse.
BL-B01D1 is a dual antibody-drug conjugate (ADC) combined with Osimertinib for treating EGFR-mutated advanced non-small cell lung cancer.
Shares of the pharmaceutical company were down 4% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。